Hansa Biopharma
Edit

Hansa Biopharma

https://hansabiopharma.com/
Last activity: 26.05.2025
Active
Categories: BioTechCareDevelopmentDiagnosticsDrugLifeMedtechResearchTime
Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company. Our vision is a world where all patients with rare immunologic diseases can lead long and healthy lives. But we often see that people with rare diseases are relegated to the impossible and left to fend for themselves. That’s not the way forward. We see all patients as equal individuals with individual needs. A point of view that gives us a unique ability to deliver the most inclusive care to everyone. For us the mission is clear – we want to develop lifesaving and life altering therapies to those who need them the most. And ultimately, we can – and will – eliminate rare diseases, one patient at a time. So how do we aim to achieve our goal? • We partner with global scientific, medical, and patient communities to identify the most urgent needs • We work relentlessly to meet the needs and create lifesaving treatments • Our lead program enables kidney transplantation in difficult-to-transplant patients, with additional clinical studies ongoing for the treatment of several acute and chronic autoimmune conditions Follow us on our journey, and we will keep you up to speed on our work to make rare diseases rarer. About us • We are based in Lund, Sweden and have operations in other European countries and in the United States • We are a biopharmaceutical company engaged in clinical development, drug discovery and commercialization • We are specialized in rare diseases within transplantation, autoimmunity, oncology and gene therapy • We are listed on Nasdaq Nordic
Likes
93
Followers
331
Followers
6.26K
Website visits
26.7K /mo.
Mentions
135
Location: Sweden, Lund
Employees: 51-200
Total raised: $70M
Founded date: 2007

Funding Rounds 1

DateSeriesAmountInvestors
17.07.2022Grant$70M-

Mentions in press and media 135

DateTitleDescription
28.05.2025Hansa Biopharma's Strategic Restructuring: A Necessary Shift for Future GrowthIn the world of biopharmaceuticals, change is the only constant. Hansa Biopharma, a pioneering company based in Lund, Sweden, is about to embark on a significant transformation. The company recently announced plans for a restructuring aimed...
26.05.2025Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiencyHansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency Mon, May 26, 2025 18:40 CET Report this content Lund, Sweden, 26 May 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today an...
26.05.2025Notice to Annual General Meeting in Hansa Biopharma AB (publ)Notice to Annual General Meeting in Hansa Biopharma AB (publ) Mon, May 26, 2025 07:00 CET Report this content Lund, Sweden May 26, 2025, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in Lund, gi...
15.05.2025A New Dawn for COPD Treatment: Dupixent's Approval in SingaporeIn a significant breakthrough for chronic obstructive pulmonary disease (COPD) patients, Singapore has approved Dupixent (dupilumab) as the first biologic treatment for this debilitating condition. This decision, announced on May 14, 2025, ...
14.05.2025Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBSHansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS Wed, May 14, 2025 08:00 CET Report this content Lund, Sweden, 14 May 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA)...
13.05.2025Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S. Tue, May 13, 2025 08:00 CET Report this content Lund, Sweden, 13 May 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that Maria ...
25.04.2025Hansa Biopharma: A New Era of Leadership and GrowthHansa Biopharma is at a crossroads. The Swedish biopharmaceutical company has just reported its first-quarter financial results for 2025, showcasing a robust growth trajectory. With a new CEO at the helm, the company is poised for a transfo...
24.04.2025Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial ResultsHansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results Thu, Apr 24, 2025 08:00 CET Report this content Strong product sales and key progress in pipeline catalysts Lund, Sweden, 24 April 2025. Hansa Biopharma ...
24.04.2025Hansa Biopharma appoints new Chief Executive OfficerHansa Biopharma appoints new Chief Executive Officer Thu, Apr 24, 2025 07:00 CET Report this content Lund, Sweden, 24 April 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced the appointment of Renée Aguiar-Lucander ...
03.04.2025Hansa Biopharma to host Q1 2025 interim results conference callHansa Biopharma to host Q1 2025 interim results conference call Thu, Apr 03, 2025 08:00 CET Report this content Lund, Sweden, 3 April, 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January - Ma...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In